130 related articles for article (PubMed ID: 17146978)
21. [Recent proposals for early stage clinical trials of cancer].
Ohashi Y
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():292-4. PubMed ID: 7986106
[TBL] [Abstract][Full Text] [Related]
22. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
Zhang Y; Mietlowski W; Chen B; Wang Y
J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
[TBL] [Abstract][Full Text] [Related]
23. Two-stage designs for phase II cancer trials with ordinal responses.
Stallard N; Cockey L
Contemp Clin Trials; 2008 Nov; 29(6):896-904. PubMed ID: 18703164
[TBL] [Abstract][Full Text] [Related]
24. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
25. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
26. Designing phase II studies in cancer with time-to-event endpoints.
Owzar K; Jung SH
Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
[TBL] [Abstract][Full Text] [Related]
27. Optimizing randomized phase II trials assessing tumor progression.
Stone A; Wheeler C; Carroll K; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
[TBL] [Abstract][Full Text] [Related]
28. Curtailed two-stage designs in Phase II clinical trials.
Chi Y; Chen CM
Stat Med; 2008 Dec; 27(29):6175-89. PubMed ID: 18816510
[TBL] [Abstract][Full Text] [Related]
29. Newer phase II trial designs gaining ground.
Benowitz S
J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
[No Abstract] [Full Text] [Related]
30. A type of sample size design in cancer clinical trials for response rate estimation.
Liu J
Contemp Clin Trials; 2011 Jan; 32(1):140-6. PubMed ID: 20965278
[TBL] [Abstract][Full Text] [Related]
31. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
Messer K; Natarajan L; Ball ED; Lane TA
Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
[TBL] [Abstract][Full Text] [Related]
32. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Sharma MR; Maitland ML; Ratain MJ
Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
[TBL] [Abstract][Full Text] [Related]
33. An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.
Kelly PJ; Stallard N; Todd S
J Biopharm Stat; 2005; 15(4):641-58. PubMed ID: 16022169
[TBL] [Abstract][Full Text] [Related]
34. Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint.
Healy BC; Ikle D; Macklin EA; Cutter G
Mult Scler; 2010 Jul; 16(7):840-7. PubMed ID: 20530124
[TBL] [Abstract][Full Text] [Related]
35. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
Lai X; Zee BC
Trials; 2015 Jun; 16():250. PubMed ID: 26037094
[TBL] [Abstract][Full Text] [Related]
36. Design and analysis of dose-finding studies combining multiple comparisons and modeling procedures.
Pinheiro J; Bornkamp B; Bretz F
J Biopharm Stat; 2006; 16(5):639-56. PubMed ID: 17037263
[TBL] [Abstract][Full Text] [Related]
37. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
Masaki N; Koyama T; Yoshimura I; Hamada C
J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
[TBL] [Abstract][Full Text] [Related]
38. [Current status and issues in clinical trials of anticancer agents].
Kojima H
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
[TBL] [Abstract][Full Text] [Related]
39. A Bayesian predictive two-stage design for phase II clinical trials.
Sambucini V
Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
[TBL] [Abstract][Full Text] [Related]
40. On Simon's two-stage design for single-arm phase IIA cancer clinical trials under beta-binomial distribution.
Liu J; Lin Y; Shih WJ
Stat Med; 2010 May; 29(10):1084-95. PubMed ID: 20077506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
